C07H - Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids

More topics under "C07H - Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids" (173,078)
C07H 1 - Processes for the preparation of sugar derivatives (12,374)
C07H 11 - Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof (1,722)
C07H 13 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids (4,753)
C07H 15 - Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals (17,975)
C07H 17 - Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals (11,681)
C07H 19 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof (20,008)
C07H 21 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids (89,892)
C07H 23 - Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin b12 (1,716)
C07H 3 - Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms (5,762)
C07H 5 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium (3,671)
C07H 7 - Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond (2,294)
C07H 9 - Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical (1,178)
C07H 99 - Subject matter not provided for in other groups of this subclass (52)

Patents for C07H - Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids (1,168)
08/2005
08/04/2005	WO2005069736A2 Transdermal delivery system for polynucleotides
08/04/2005	CA2554322A1 Transdermal delivery system for polynucleotides
08/03/2005	EP1558624A1 Continuous process for the preparation of fructopyranose sulfamate derivatives
08/02/2005	US6924271 Having immunomodulatory activity, for therapy and prophylaxis of diseases
07/2005
07/28/2005	WO2005035545A3 Single nucleotide polymorphism analysis of highly polymorphic target sequences
07/28/2005	WO2005033121A3 Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
07/20/2005	CN1642966A Isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
07/20/2005	CN1211089C Application of uridine phosphorylase inhibitor and composition containing the same
07/14/2005	US20050153306 Libraries; peptide nucleic acids; for assaying hydrolases/proteases
07/12/2005	CA2146047C 13-substituted milbemycin derivatives, their preparation and use
07/06/2005	CN1636008A Macrolide antiinfective agents
06/2005
06/30/2005	WO2005058931A2 Methods and algorithms for identifying genomic regulatory sites
06/30/2005	WO2005058930A2 Methods for production of recombinant vascular endothelial cell growth inhibitor
06/29/2005	EP1546312A2 Glucose transport mutants for production of biomaterial
06/29/2005	EP1444244B1 Method for the production of desclarithromycin, and intermediate products
06/29/2005	CN1633495A Methods and compositions for generating a genetically modified animal using lentiviral vectors
06/23/2005	WO2005056570A2 Production of amino sugars
06/23/2005	WO2005056569A2 Beta integrin gene and protein
06/23/2005	CA2546914A1 Production of amino sugars
06/15/2005	EP1539188A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
06/09/2005	WO2005051967A2 Oligonucleotides labeled with a plurality of fluorophores
06/09/2005	WO2005021563A3 Method and materials for bisulfite conversion of cytosine to uracil
06/02/2005	US20050118623 Single nucleotide polymorphism analysis of highly polymorphic target sequences
06/02/2005	US20050118611 Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
06/01/2005	CN1622995A Receptor nucleic acids and polypeptides
05/2005
05/26/2005	WO2005047300A2 Improved methods and compositions for rna interference
05/26/2005	US20050113326 Gene expression inhibition; connective tissue growth factor modulators; nucleosides, phosphorothioate/phosphodiester linkages; metabolic diseases, diabetes
05/26/2005	CA2545182A1 Improved methods and compositions for rna interference
05/17/2005	US6894032 Or salt thereof
05/12/2005	WO2005042552A2 Modulation of sglt2 expression
05/12/2005	WO2004063209A3 Methods of producing c-aryl glucoside sglt2 inhibitors
05/12/2005	US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders
05/06/2005	WO2005040180A2 Antisense modulation of superoxide dismutase 1, soluble (sod-1) expression
05/05/2005	US20050095623 Reacting nucleic acids with magnesium/sodium bisulfite in presence of polyamine catalyst (guanidine) to create point mutations; kits
05/04/2005	CN1612889A 3-b-d-ribofuranosylthiazolo [4, 5-d] pyridimine nucleosides and uses thereof
05/03/2005	US6887990 For improved yield/purification; comprises attachment to a substrate; genomics/diagnostics
04/2005
04/28/2005	WO2005038013A1 Artisense oligonucleotides optimized for kidney targeting
04/21/2005	WO2005035545A2 Single nucleotide polymorphism analysis of highly polymorphic target sequences
04/21/2005	WO2002057425A3 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
04/21/2005	CA2540551A1 Single nucleotide polymorphism analysis of highly polymorphic target sequences
04/14/2005	WO2005033121A2 Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs
04/14/2005	WO2004044140A3 2’-substituted oligomeric compounds and compositions for use in gene modulations
04/12/2005	CA2131229C Bisconjugates comprising two saccharides and a spacer
04/07/2005	WO2004043978A3 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
03/2005
03/31/2005	WO2005028489A2 Novel adenosine a3 receptor agonists
03/31/2005	WO2004052899A3 Process for the production of 2'-branched nucleosides
03/31/2005	US20050069992 Producing stabilized, meltable, hydrophilic, starch derived, amylose and amylopectin host molecules capable of forming clathrates; emulsification or encapsulation of food products/additives/supplements
03/31/2005	CA2537094A1 Novel adenosine a3 receptor agonists
03/29/2005	US6872707 Prevention, therapy of bacteria infections
03/24/2005	US20050065110 Synergistic mixture; antioxidant; cardiovascular disorders; antidiabetic agents
03/22/2005	US6870047 Magnetic pigment
03/10/2005	WO2005021563A2 Method and materials for bisulfite conversion of cytosine to uracil
03/02/2005	CN1191266C Compositions for treating inflammatory response
03/02/2005	CN1191263C 3-deoxy-desmycosin derivatives and process for their preparation
02/2005
02/24/2005	WO2005016947A2 ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION
02/24/2005	US20050043394 For prophylaxis and therapy of diabetes mellitus, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases, neuropathic diseases, neuropathic pain and polyneuropathy; free fatty acids and/or fatty acid esters and uridine, deoxyuridine, uridine monophosphate, deoxyuridine monophosphate
02/24/2005	US20050043269 Pharmaceutically active uridine esters
02/24/2005	US20050043256 antisense oligonucleotides, are targeted to a nucleic acid encoding stearoyl-CoA desaturase, and modulate the expression of stearoyl-CoA desaturase; gene therapy; genetic engineering; for treatment of abnormal lipid metabolism, obesity
02/24/2005	US20050043248 Novel lincomycin derivatives possessing antimicrobial activity
02/17/2005	WO2005014607A2 Antisense modulation of stearoyl-coa desaturase expression
02/17/2005	WO2004033471A3 Glucose transport mutants for production of biomaterial
02/17/2005	US20050037980 Substituted fused heterocyclic C-glycosides
02/16/2005	CN1582156A Methods for treating ocular neovascular diseases
02/10/2005	WO2005012320A2 Novel lincomycin derivatives possessing antimicrobial activity
02/10/2005	WO2005012318A2 Substituted fused heterocyclic c-glycosides
02/10/2005	WO2005012317A2 Amylose and amylopectin derivatives
02/10/2005	CA2549015A1 Substituted fused heterocyclic c-glycosides
02/10/2005	CA2528592A1 Novel lincomycin derivatives possessing antimicrobial activity
02/09/2005	EP1280535B1 Processes for preparing clarithromycin polymorphs
02/03/2005	WO2005010016A2 Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
02/03/2005	US20050026278 RNA interference mediating small RNA molecules
02/03/2005	CA2533691A1 Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
02/02/2005	CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
01/2005
01/27/2005	WO2005007663A2 Fluorogenic enzyme substrates and uses thereof
01/27/2005	US20050020825 Reacting a D-fructose with CaO to obtain a 2-C-methyl-D-ribonic- gamma -lactone; reducing, coupling with unprotected base such as cytosine in presence of silylating agent
01/27/2005	US20050019915 Oligonucleotides for use in controlling expression of gene coding polypeptide associated with catalyzing the dismutation of superoxide to hydrogen peroxide; antiproliferative agents; antitumor agents; gene expression inhibition
01/26/2005	EP1499187A2 Immunostimulatory g,u-containing oligoribonucleotides
01/20/2005	WO2004043977A3 2’-fluoro substituted oligomeric compounds and compositions for use in gene modulations
01/19/2005	CN1568373A RNA interference mediating small rna molecules
01/06/2005	WO2005000859A2 Novel reagent compounds and methods of making and using the same
12/2004
12/28/2004	CA2331297C Hygromycin a derivatives
12/23/2004	US20040259248 RNA interference mediating small RNA molecules
12/23/2004	US20040259247 short interfering RNAs for use treating diseases, in protein separation or purification, in drug screening; cell with target gene-specific knockout phenotype; double stranded RNA; RNA fragments are the sequence-specific mediators of RNAi (RNA interference)
12/22/2004	EP1489422A2 Multisignal labeling reagents, processes and uses therefor
12/22/2004	EP1487978A2 An improved method for synthesising templated molecules
12/15/2004	EP1486210A1 Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
12/15/2004	EP1485393A2 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives
12/07/2004	CA2352332C Hygromycin a derivatives
12/02/2004	US20040242910 Polyol fatty acid polyesters process and polyurethanes therefrom
11/2004
11/25/2004	WO2003086280A3 Immunostimulatory g,u-containing oligoribonucleotides
11/25/2004	US20040234634 Pharmaceutical compositions having appetite suppressant activity
11/18/2004	WO2004099227A2 Polyol fatty acid polyesters process and polyurethanes therefrom
11/18/2004	US20040229266 RNA interference mediating small RNA molecules
11/18/2004	US20040228935 Plant extract comprising steroidal glycosides from the genus Trichocaulon or Hoodia produced by solvent extraction
11/17/2004	EP0679160B1 Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
11/03/2004	EP1267892B1 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
11/02/2004	US6812219 Methods and compositions for treating flaviviruses and pestiviruses
10/2004
10/20/2004	CN1539014A Templated molecules and methods for using such molecules
10/19/2004	CA2238574C Targeted cytotoxic anthracycline analogs
10/13/2004	EP1465981A2 Methods and compositions for generating a genetically modified animal using lentiviral vectors

1 2 3 4 5 6 7 8 9 10 11 12